^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Bowens Disease

Related cancers:
24d
Immunoexpression of Ki67, P16 and Beta-catenin in precursor lesions of cutaneous squamous cell carcinoma. (PubMed, Rom J Morphol Embryol)
The immunoreactivity to the investigated markers confirms the multistage skin carcinogenesis, and their involvement starting from the initiation phase of the cancer process. The importance of the studied markers in the evolution and prognosis of precancerous lesions of CSCC is also supported by the linear correlations revealed between the immunoexpressions of P16, Ki67 and the membranous immunoexpression of Beta-catenin in AK.
Journal
|
CTNNB1 (Catenin (cadherin-associated protein), beta 1)
|
CTNNB1 expression
25d
Efficacy and Safety of Carbon Dioxide Laser Ablation Combined with Manual Dermabrasion and Intralesional 5-Fluorouracil Injection in Bowen's Disease. (PubMed, Indian Dermatol Online J)
The study was limited by retrospective study design, small sample size, and no comparison with standard therapy. Combination approach using carbon dioxide laser ablation followed by manual dermabrasion and IL 5-FU injection has been proved to be effective, efficient and safe with good functional, oncological and aesthetic outcomes in treating BD.
Journal
|
IL5 (Interleukin 5)
|
5-fluorouracil
29d
Yes-associated protein (YAP) promotes invasion and migration of cutaneous squamous cell carcinoma cells by activating the PI3K/AKT pathway (PubMed, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi)
The expression of E-cadherin was increased, while the expression of snail, β-catenin, p-AKT, p-S6 and p-4EBP1were decreased. Conclusion YAP is highly expressed in cSCC tissues, and promotes the cell migration and invasion of cSCC cells by activating the PI3K/AKT signaling pathway and EMT.
Journal
|
CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CDH1 (Cadherin 1) • YAP1 (Yes associated protein 1) • EIF4EBP1 (Eukaryotic translation initiation factor 4E binding protein 1) • SNAI1 (Snail Family Transcriptional Repressor 1)
|
CDH1 expression
1m
A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC (clinicaltrials.gov)
P2, N=44, Completed, Sirnaomics | Active, not recruiting --> Completed | N=100 --> 44
Trial completion • Enrollment change
1m
Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Adults With Facial isSCC (clinicaltrials.gov)
P1/2, N=9, Completed, Sirnaomics | Active, not recruiting --> Completed | N=30 --> 9 | Trial completion date: Jul 2023 --> Mar 2023 | Trial primary completion date: Jul 2023 --> Mar 2023
Trial completion • Enrollment change • Trial completion date • Trial primary completion date
2ms
Incidence and survival rates of primary cutaneous malignancies in Korea, 1999-2019: A nationwide population-based study. (PubMed, J Dermatol)
The 5-year relative survival rates steadily increased in extramammary Paget's disease (23.6%), cutaneous B-cell lymphoma (21.3%), mycosis fungoides (20.2%), extranodal NK/T-cell lymphoma, nasal type (18.1%), and malignant melanoma (16.1%) from 1996-2000 to 2015-2019. Most primary cutaneous malignancies have increased in incidence and survival rates in the Korean population, but to varying extents depending on the type of skin cancer.
Journal
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
2ms
Human papillomavirus Detection Rates in Bowen's Disease: Correlation with Pelvic and Digital Region Involvement and Specific p53 Immunostaining Patterns. (PubMed, Clin Exp Dermatol)
Our findings suggest the oncogenic role of sexually transmitted and genito-digitally transmitted α-HPVs in pathogenesis of BD in the pelvic and digital regions.
Journal
|
TP53 (Tumor protein P53)
3ms
Expression Analysis of Retinal G Protein-coupled Receptor and its Correlation with Regulation of the Balance between Proliferation and Aberrant Differentiation in Cutaneous Squamous Cell Carcinoma. (PubMed, Acta Derm Venereol)
In addition, RGR expression was inversely correlated with involucrin expression and positively correlated with proliferating cell nuclear antigen (PCNA) and Ki67 expression. Furthermore, RGR regulates SCC cell differentiation through the PI3K-Akt signalling pathway, as determined using molecular biology approaches in vitro, suggesting that high expression of RGR is associated with aberrant proliferation and differentiation in SCC.
Journal
|
PCNA (Proliferating cell nuclear antigen)
3ms
Review of the European Society for Photodynamic Therapy (Euro-PDT) Annual Congress 2022. (PubMed, Eur J Dermatol)
Over-expression of the proto-oncogene, Myc, has been observed in poor responders, whilst the tumour suppressor gene, PTEN, showed under-expression. The potential for use and methods of delivery of topical PDT for dermatological indications continue to expand the enhanced choice of treatment offered to patients.
Review • Journal
|
PTEN (Phosphatase and tensin homolog)
|
MYC expression
3ms
Extra-Ocular Sebaceous Carcinoma in Situ of the Arm of an Elder Male: An Unusual Presentation in an Atypical Location. (PubMed, Int J Surg Pathol)
This report underscores the importance of considering sebaceous carcinoma in situ in diagnosis in atypical locations, emphasizing the need for a comprehensive histopathologic examination and immunohistochemical staining panel. This article aims to demonstrate the rarity of sebaceous carcinoma in situ in extraocular sites to broaden our understanding of its diverse clinical presentations.
Journal
|
MSI (Microsatellite instability) • AR (Androgen receptor) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • PMS2 (PMS1 protein homolog 2) • KRT7 (Keratin-7) • TP63 (Tumor protein 63) • PLIN2 (Perilipin)
3ms
Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia (clinicaltrials.gov)
P2, N=25, Recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Jan 2024 --> Jan 2025
Trial completion date • Trial primary completion date • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Keytruda (pembrolizumab)
4ms
Trial completion date • Trial primary completion date
|
fluorouracil topical
5ms
Expression of p53, p63, p16, Ki67, Cyclin D, Bcl-2, and CD31 Markers in Actinic Keratosis, In Situ Squamous Cell Carcinoma and Normal Sun-Exposed Skin of Elderly Patients. (PubMed, J Clin Med)
The study identifies distinct differences in the presence of amorphous masses and the expression levels of p53, Bcl-2, and CD31 between sun-exposed skin and in situ cutaneous squamous cell carcinomas, including actinic keratoses.
Journal • IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • CD31 (Platelet and endothelial cell adhesion molecule 1) • TP63 (Tumor protein 63) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
|
BCL2 expression • TP53 expression • CD31 expression
5ms
New P2 trial
5ms
A Case of Biphenotypic Adnexal Carcinoma With Bowenoid and Basaloid Features: Focus on the Expression of SOX9 and Wnt Signaling Pathway Molecules, Including CDX2. (PubMed, Am J Dermatopathol)
After complete excision, no recurrence has been observed for 5 months. The findings of the present case expand the histological spectrum of cutaneous adnexal tumors with follicular immunophenotypic differentiation.
Journal
|
CTNNB1 (Catenin (cadherin-associated protein), beta 1) • SOX9 (SRY-Box Transcription Factor 9) • CDX2 (Caudal Type Homeobox 2) • YBX1 (Y-Box Binding Protein 1) • SYP (Synaptophysin)
|
SOX9 expression
5ms
Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia (clinicaltrials.gov)
P1, N=13, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2023 --> Nov 2024
Trial completion date
|
Zyclara (imiquimod) • fluorouracil topical
6ms
Long non-coding RNA PVT1 is overexpressed in cutaneous squamous cell carcinoma and exon 2 is critical for its oncogenicity. (PubMed, Br J Dermatol)
Our study reveals a previously unrecognized role for exon 2 of PVT1 in its oncogenic role and that PVT1 suppresses cellular senescence in cSCC. PVT1 may be a biomarker and therapeutic target in cSCC.
Journal
|
CDKN1A (Cyclin-dependent kinase inhibitor 1A) • PVT1 (Pvt1 Oncogene)
|
MYC expression
7ms
Comparison of the clinical characteristics of benign and malignant eyelid lesions: an analysis of 1423 eyelid lesions, compared between ophthalmology department and plastics department. (PubMed, Graefes Arch Clin Exp Ophthalmol)
Eyelid lesions in patients aged 76 or older are more likely to be malignant. Ophthalmology eyelid specimens in younger patients are more commonly benign and related to inflammation. Specimens from the plastics department are more commonly malignant, related to UV-exposure, and are from older patients. This difference may be due to a misconception that plastic surgeons have more eyelid cancer reconstruction experience than oculoplastic surgeons, or less awareness of the oculoplastic expertise available today.
Journal
7ms
Survival of patients with basal cell carcinoma, squamous cell carcinoma and squamous cell carcinoma in situ: A whole population study. (PubMed, J Am Acad Dermatol)
Our whole population cohort survival study examining the Icelandic Cancer Registry supports prior studies demonstrating that BCC is not associated with a reduction in relative survival and that SCC and SCCis are associated with comparatively poor relative survival in certain population subgroups.
Journal
7ms
Squamous cell carcinoma of the eyelid. (PubMed, Jpn J Clin Oncol)
Local chemotherapy, such as imiquimod and 5-fluorouracil, may be used for eyelid squamous cell carcinoma in situ. When surgery or radiotherapy is not recommended for distant metastases or locally advanced disease, drug therapy is often according to head and neck squamous cell carcinoma in Japan. The treatment often requires a multidisciplinary team to ensure the preservation of function and cosmetic appearance.
Journal
|
5-fluorouracil • Zyclara (imiquimod)
7ms
Two cases of cutaneous sarcomatoid squamous cell carcinoma resembling cutaneous giant cell tumor of soft tissue (ASDP 2023)
Molecular analysis may also be helpful as H3F3 mutation or HMGA2-NCOR2 fusion would be evidence of GCT bone or GCT soft tissue rather than cSSCC. Poster type: Poster Defense
Clinical
|
TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • FAT1 (FAT atypical cadherin 1) • NCOR2 (Nuclear Receptor Corepressor 2) • CD68 (CD68 Molecule) • HMGA2 (High mobility group AT-hook 2) • SH2B3 (SH2B Adaptor Protein 3) • TP63 (Tumor protein 63) • KRT5 (Keratin 5)
8ms
Functionally distinct cancer-associated fibroblast subpopulations establish a tumor promoting environment in squamous cell carcinoma. (PubMed, Nat Commun)
These findings are cSCC-specific and could not be recapitulated in basal cell carcinomas. Our study provides important insights into the potential origin and functionalities of dermal CAFs that will be highly beneficial for the specific targeting of the cSCC microenvironment.
Journal
8ms
Experience analysis of a combined photodynamic/electrodesiccation therapy in the treatment of 11 cases of large patches of Bowen's disease. (PubMed, Photodiagnosis Photodyn Ther)
ET combined with PDT is effective in the treatment of BD with large patches and has the advantages of fast healing, less scar formation, and a good cosmetic effect.
Journal
8ms
Surgical excision versus topical 5% 5-fluorouracil and photodynamic therapy in treatment of Bowen's disease: a multicenter randomized controlled trial. (PubMed, J Am Acad Dermatol)
For MAL-PDT non-inferiority to excision cannot be concluded. Therefore, 5-fluorouracil should be preferred over excision and MAL-PDT in treatment of Bowen's disease.
Journal
|
5-fluorouracil • fluorouracil topical
8ms
Superficial Spreading Cervical Squamous Cell Carcinoma In Situ Replacing the Endometrium: Report of 2 Cases With Biomarker Studies (CAP 2023)
The decreased or loss of expression of CD138 and E-cadherin might be correlated with tumor invasion and progression to cervical invasive SCC. In both of our cases, CD138 and membranous E-cadherin were strongly expressed in tumor cells, suggesting a role in the pathogenesis of superficial spreading cervical SCC to endometrium (Figure 2.77, C, D).
Clinical
|
CDH1 (Cadherin 1) • SDC1 (Syndecan 1)
|
CDH1 expression
8ms
Podoplanin-positive cells located in the basal layer of Bowen disease include tumor cells with cancer stem cell properties. (PubMed, J Dermatol)
These results indicate that PDPN-positive cells include tumor cells with cancer stem cell properties. Although the precise mechanism through which PDPN expression is involved in the pathogenesis of Bowen disease needs to be determined, PDPN may be a novel druggable target for Bowen disease.
Journal • Cancer stem • Tumor cell
8ms
Journal
|
TRPS1 (Transcriptional Repressor GATA Binding 1)
8ms
Electrodesiccation and Curettage for Squamous Cell Carcinoma in Situ: The Effect of Anatomic Location on Local Recurrence. (PubMed, Dermatol Surg)
Electrodesiccation and curettage allows for a high 5-year cure rate across a broad range of anatomic sites. However, overall cure rate should be individualized by anatomic location when counseling patients.
Journal
8ms
Ultrastructural and morphological analysis during progression of Bowen disease reveals a complex interplay between hyperkeratosis, cytokeratin expression, host immunity and amyloid deposition. (PubMed, Eur J Dermatol)
The expression of cytokeratins, hyperkeratosis, inflammatory infiltration and amyloid deposition are useful findings indicating the "stage" in Bowen disease.
Journal
8ms
Evaluating the safety and efficacy of aminolevulinic acid 20% topical solution activated by pulsed dye laser and blue light in the treatment of facial cutaneous squamous cell carcinoma in situ. (PubMed, J Cosmet Dermatol)
The ALA-PDL-PDT protocol is a safe and well-tolerated treatment option for isSCC on the face, providing excellent cosmetic and functional results.
Journal
9ms
Association between HPV infection and penile cancer and penile intraepithelial neoplasia: a retrospective observational study. (PubMed, J Eur Acad Dermatol Venereol)
This study shows a prevalence of HPV-DNA in penile SCC and premalignant lesions of 45.5% and 92.9%, respectively. Identifying HPV involvement in SCC and PeIN pathology has the potential to guide treatment and enhance follow-up strategies.
Observational data • Retrospective data • Journal
9ms
Eccrine Ductal Carcinoma of the Eyelid. (PubMed, Ophthalmic Plast Reconstr Surg)
The invasive eccrine ductal carcinoma only mildly thickened the tarsal plate and was most likely an incidental finding in a biopsy prompted by the squamous cell carcinoma in situ. The 5-year relative survival rate for malignant apocrine-eccrine tumors is approximately 97%, and our patient is alive and without evidence of local or distant tumor recurrence 5.5 years following the excision of her eyelid tumor.
Journal
10ms
Clinical, dermoscopic, and histopathologic findings of hidroacanthoma simplex: a case report and literature review. (PubMed, Dermatol Reports)
We report a case of HS that changes its clinical appearance, dermoscopy, and histopathologic findings over time. Differential diagnoses included seborrheic keratosis, Bowen disease, melanoma, and malignant HS.
Review • Journal
10ms
Treatment options and prognosis of patients with lung squamous cell cancer in situ: a comparative study of lung adenocarcinoma in situ and stage IA lung squamous cell cancer. (PubMed, Transl Lung Cancer Res)
Surgery was an independent favorable prognostic factor for the LSCIS patients. Lobectomy was a superior choice of surgical procedure, and significantly improved the current outcomes of the LSCIS patients.
Journal
10ms
New topical agents for actinic keratoses: clinical and OCT evaluation (WCD 2023)
OBSERVATION: Among available treatments, it is possible to distinguish lesion-directed therapies (cryotherapy, laser therapy, conventional photodynamic theapy and surgery when a progression to iSCC is suspected) and field-directed therapies (5-fluorouracil, diclofenac,piroxicam, imiquimod and daylight photodynamic therapy)associated to daily appropriate photoprotection...We evaluated efficacy, safety and adherence to therapy of topical ointments indicated for the treatment of the different clinico-pathologic variants of AK (focusing on tirbanibulin and 5-Fluorouracil 0.5%, Salicylic Acid 10%), providing a clinical, dermoscopic and OCT longitudinal evaluation...Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis...2021;384(6):512-520. doi:10.1056/NEJMoa2024040
Clinical
|
Zyclara (imiquimod) • Klisyri (tirbanibulin ointment)
10ms
Real World Experience of Topical Tirbanibulin Eradication of Squamous Cell Carcinoma with Histologic Confirmation (WCD 2023)
This demonstrates a novel therapy for SCC and SCCIS. Prospective studies of topical tirbanibulin for the treatment of SCC are warranted
Clinical • Real-world evidence • Real-world
|
Klisyri (tirbanibulin ointment)